Hawthorn executes deal with university
MADISON — Hawthorn Pharmaceuticals Inc. has struck a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer.
Under the terms of the agreement, Madison-based Hawthorn will receive an exclusive worldwide license to develop and commercialize the antibody portfolio.
“We are excited to be working with the world=-class cancer scientists at University of Pittsburgh’s Cancer Institute who have devoted their entire careers to improving people’s lives through cancer discovery,” said Rob Lewis, chief scientific officer at Hawthorn.
“There are many strengths created by our relationship with the University of Pittsburgh that promotes the rapid development of these novel antibodies,” said Max Draughn, president and CEO of Hawthorn. “Our collaboration is a shared vision to ultimately extend and improve the lives of many children and adults who suffer with various cancers.”
To sign up for Mississippi Business Daily Updates, click here.
Recent Posts
- Bureau selects directors
- Entergy announces changes
- MSU’s Quarles honored by ASPA
- BancorpSouth makes promotions
- BOOK BIZ: Neshoba Fair photo book is sure to draw interest
- Board honors Morrison
- Q&A: Thomas Broadus, director of interactive & news media, The Focus Group
- Entergy recognizes Stedman
2011 MBJ BUSINESSPERSON OF THE YEAR
2011 MBJ BUSINESSPERSON OF THE YEAR: SURVIVING THE STORM


![[Print]](http://msbusiness.com/wp-content/plugins/dmc_sociable_toolbar/print.png)
![[Email]](http://msbusiness.com/wp-content/plugins/dmc_sociable_toolbar/email_2.png)
![[RSS Feed]](http://msbusiness.com/wp-content/plugins/dmc_sociable_toolbar/rssfeed.png)
![[del.icio.us]](http://msbusiness.com/wp-content/plugins/dmc_sociable_toolbar/delicious.png)
![[Digg]](http://msbusiness.com/wp-content/plugins/dmc_sociable_toolbar/digg.png)
![[Facebook]](http://msbusiness.com/wp-content/plugins/dmc_sociable_toolbar/facebook.png)
POST A COMMENT